title: [Experience of an adherence support for HIV-1 seropositive patients with failure under treatment].
abstract: BACKGROUND
  To be successful highly active antiretroviral therapies need very high levels of adherence to be successful. In need to help patients in dealing with adverse effects, complexity and multiple constraints of these drugs, adherence support programs have been developed. Therefore, the efficacy on viral load of these interventions has not been established in the HIV-1 positive population. The aim of our study was to assess the virological efficacy of this type of program in our institution.
  
  
  METHODS
  Non randomized intervention study with a control group. The intervention group was constituted of patients presenting with virological failure who where admitted in the adherence program. The control group (2:1) has been selected in our data base. Factors known to influence viral load have been analyzed by multiple logistic regression.
  
  
  RESULTS
  The probability of obtaining a significant decrease of viral load was better at 6 months for patients using the adherence program (OR: 4,48 [2,72-11,8]). This benefit was not sustained at 12 months. The program efficacy varied with the kind of treatment (with or without protease inhibitors), the therapeutic history and the initial viral load. The absence of protease inhibitor, a high initial viral load, small number of previous drugs were linked to viral load decrease.
  
  
  CONCLUSIONS
  The good virological results observed at 6 months in the intervention group are incentive. Long term virological gain and the profile of patients who could make the best of an adherence support program have to be determined.
authors.affiliation: Cisih de Midi-Pyrénées, hôpital Purpan, 31059 Toulouse cedex, France. cylrildelpierre@yahoo.fr
authors.forename: C
authors.initials: C
authors.lastname: Delpierre
authors.forename: F
authors.initials: F
authors.lastname: Hurlupé
authors.forename: L
authors.initials: L
authors.lastname: Cuzin
authors.forename: F
authors.initials: F
authors.lastname: Balsarin
authors.forename: B
authors.initials: B
authors.lastname: Rousselle-Koch
authors.forename: A
authors.initials: A
authors.lastname: Grand
authors.forename: P
authors.initials: P
authors.lastname: Massip
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D010349:Patient Compliance; D013997:Time Factors; D017211:Treatment Failure